Literature DB >> 22999133

Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6.

Andrew H Briggs1, Milton C Weinstein, Elisabeth A L Fenwick, Jonathan Karnon, Mark J Sculpher, A David Paltiel.   

Abstract

A model's purpose is to inform medical decisions and health care resource allocation. Modelers employ quantitative methods to structure the clinical, epidemiological, and economic evidence base and gain qualitative insight to assist decision makers in making better decisions. From a policy perspective, the value of a model-based analysis lies not simply in its ability to generate a precise point estimate for a specific outcome but also in the systematic examination and responsible reporting of uncertainty surrounding this outcome and the ultimate decision being addressed. Different concepts relating to uncertainty in decision modeling are explored. Stochastic (first-order) uncertainty is distinguished from both parameter (second-order) uncertainty and from heterogeneity, with structural uncertainty relating to the model itself forming another level of uncertainty to consider. The article argues that the estimation of point estimates and uncertainty in parameters is part of a single process and explores the link between parameter uncertainty through to decision uncertainty and the relationship to value of information analysis. The article also makes extensive recommendations around the reporting of uncertainty, in terms of both deterministic sensitivity analysis techniques and probabilistic methods. Expected value of perfect information is argued to be the most appropriate presentational technique, alongside cost-effectiveness acceptability curves, for representing decision uncertainty from probabilistic analysis.
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Mesh:

Year:  2012        PMID: 22999133     DOI: 10.1016/j.jval.2012.04.014

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  182 in total

1.  Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.

Authors:  Salah Ghabri; Françoise F Hamers; Jean Michel Josselin
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981

Review 2.  Structural Design and Data Requirements for Simulation Modelling in HIV/AIDS: A Narrative Review.

Authors:  Xiao Zang; Emanuel Krebs; Linwei Wang; Brandon D L Marshall; Reuben Granich; Bruce R Schackman; Julio S G Montaner; Bohdan Nosyk
Journal:  Pharmacoeconomics       Date:  2019-10       Impact factor: 4.981

3.  "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.

Authors:  Fernando Alarid-Escudero; Eva A Enns; Karen M Kuntz; Tzeyu L Michaud; Hawre Jalal
Journal:  Value Health       Date:  2019-05       Impact factor: 5.725

4.  Massachusetts Health Reform Cost Less and Was More Effective for Uninsured Individuals With Venous Thromboembolism: A Cost-Effectiveness Analysis.

Authors:  Alok Kapoor; Nicholas Shaffer; Amresh Hanchate; Mark Roberts; Kenneth Smith
Journal:  Med Care       Date:  2016-05       Impact factor: 2.983

5.  Decision-analytic models: current methodological challenges.

Authors:  J Jaime Caro; Jörgen Möller
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

Review 6.  Exploring structural uncertainty in model-based economic evaluations.

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon
Journal:  Pharmacoeconomics       Date:  2015-05       Impact factor: 4.981

7.  Understanding the economic impact of intravascular ultrasound (IVUS).

Authors:  Alessandro Alberti; Pietro Giudice; Alessandra Gelera; Luca Stefanini; Virginia Priest; Michael Simmonds; Christa Lee; Matthew Wasserman
Journal:  Eur J Health Econ       Date:  2015-02-11

8.  Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models.

Authors:  Anthony J Hatswell; Ash Bullement; Andrew Briggs; Mike Paulden; Matthew D Stevenson
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

9.  Multiobjective Calibration of Disease Simulation Models Using Gaussian Processes.

Authors:  Aditya Sai; Carolina Vivas-Valencia; Thomas F Imperiale; Nan Kong
Journal:  Med Decis Making       Date:  2019-08-02       Impact factor: 2.583

10.  Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Authors:  Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.